Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
5.26
-0.25 (-4.63%)
At close: Sep 11, 2026, 4:00 PM EDT
5.32
+0.07 (1.24%)
After-hours: Sep 11, 2026, 7:43 PM EDT
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $1.63M in the quarter ending June 30, 2026, a decrease of -8.33%. This brings the company's revenue in the last twelve months to $8.22M, down -51.05% year-over-year. In the year 2025, Aclaris Therapeutics had annual revenue of $7.83M, down -58.19%.
Revenue (ttm)
$8.22M
Revenue Growth
-51.05%
P/S Ratio
95.28
Revenue / Employee
$112,589
Employees
73
Market Cap
783.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.83M | -10.89M | -58.19% |
| Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
| Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
| Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
| Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
| Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
| Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
| Dec 31, 2018 | 6.15M | 4.47M | 265.48% |
| Dec 31, 2017 | 1.68M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Geron | 204.56M |
| 4D Molecular Therapeutics | 92.01M |
| Crescent Biopharma | 11.88M |
| DBV Technologies | 5.04M |
| Silence Therapeutics | 615.00K |
ACRS News
- 3 days ago - Aclaris Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 10 days ago - Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 12 days ago - Canaccord starts Aclaris with Buy on ‘sizeable’ U.S. opportunities - TheFly
- 12 days ago - Aclaris Therapeutics initiated with a Buy at Canaccord - TheFly
- 5 weeks ago - Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib - TheFly
- 5 weeks ago - Aclaris Therapeutics files automatic mixed securities shelf - TheFly
- 5 weeks ago - Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics reports Q2 EPS (15c), consensus (16c) - TheFly